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ABSTRACT 
The main objective was to study drug resistance mutations (DRM) in the 
HIV-1 reverse transcriptase (RT) gene of minor HIV-1 quasispecies, not 
detectable with standard techniques. Sensitive allele-specific PCR (AS-
PCR) and next-generation sequencing (NGS) were developed to study 
resistance to drugs of relevance in low- and middle-income countries 
(LMIC); the nucleoside analogue RT inhibitor (NRTI) lamivudine (3TC) 
and the non-nucleoside RT inhibitors (NNRTIs) efavirenz (EFV) and 
nevirapine (NVP).  
In Paper I and II, AS-PCR was used to detect M184I/V mutations which 
confer high-level resistance to 3TC. We addressed the selection of drug-
resistant HIV quasispecies occurs during the initial phase of viral decay 
after treatment initiation and their emergence in two viral reservoirs, blood 
plasma and cerebrospinal fluid (CSF). Selection of M184I/V was found to 
be rare during the first phase of viral decay in patients with primary HIV-
1infection (PHI) or advanced chronic infection initiated on a three- or four- 
drug antiretroviral treatment (ART), containing 3TC. In contrast, drug-
resistant quasispecies were more commonly detected in patients given dual 
ART, implicating that highly potent ART is necessary to avoid drug 
resistance during the early phase of viral decay. In patients who had ART-
failure during 3TC containing therapy differences in drug resistance 
patterns, in both minor and major viral populations, were observed in the 
blood and CSF. However, the differences observed were most likely a 
result of differences in the selective pressure of ART rather than unique 
evolutionary pathways.   
In Paper III, in order to study transmitted drug resistance (TDR) AS-PCR 
was used to detect K103N and Y181C mutations, which confer high-level 
resistance NVP and EFV, in treatment-naïve patients from Ethiopia, from 
East Africans and Caucasians living in Stockholm. The AS-PCR was 
highly sensitive and detected K103N and Y181C in minor quasispecies in 
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both subtype B (HIV-1B) and subtype C (HIV-1C) infected patients. 
These NNRTI mutations were found in the minor HIV-1 populations in all 
three patient groups.  
In Paper IV, we developed a feasible, cost-efficient and easy-to-use high 
throughput NGS protocol for detection RTI mutations, including M184V, 
K103N and Y181C, to be applied in large scale surveillance of DRM in 
LMIC. The NGS assay was applicable to both HIV-1 C and HIV-1 B. It 
showed good concordance with standard population sequencing in 
detecting major DRMs and was also able to detect additional low 
abundance DRMs. 
In summary, standard population sequencing assays underestimate the 
prevalence of important DRM in ART naïve and ART experienced 
patients. AS-PCR and easy to use high throughput assays can be useful in 
large scale surveillance in LMIC and to address the clinical significance of 
drug resistance in minor HIV-1 quasispecies.     
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1 A GLANCE AT THE HIV PANDEMIC TODAY 
When the antiretroviral drug zidovudine (AZT), was introduced as the first 
therapy of human immunodefciency virus type 1 (HIV-1) infection in 1987 
(1), it gave hope of finding a cure within a near future. The antiviral 
activity of AZT, did not only indicate that the infection could be 
controlled, it also evoked optimism to search possible strategies to 
eradicate the virus from the body. Today, more than 30 years later after the 
HIV-1 discovery (2-4) and despite that tremendous scientific advances 
have been gained, the hope of a possible cure is still only a hope. In the 
absence of a potent cure, antiretroviral therapy (ART) has become a very 
important achievement and breakthrough in controlling the HIV disease 
progression and thereby has saved countless of lives over the years in the 
fight towards HIV and acquired immunodeficiency syndrome (AIDS).  
Currently, about 35.3 million people are living with HIV worldwide (5). 
As a result of the 2000 United Nations Millennium Declaration to initiate a 
global response to the HIV/AIDS- crisis (6, 7), major advances have been 
done to halt the pandemic. Together with the establishment of the health 
initiatives, such as The United States President´s Emergency Plan for 
AIDS Relief (PEPFAR) (8) and the Global Fund to Fight AIDS, 
Tuberculosis and Malaria (9), a rapid scale-up of ART globally has been 
accomplished and a decline in new HIV infections as well as AIDS-related 
deaths have been observed during the recent years (5). 
At the end of 2012, approximately 10.6 million people living with HIV 
were receiving ART. The biggest change in access to ART has occurred in 
low-and middle-income countries (LMIC), where the HIV prevalence is 
also the highest (Figure 1). The number of people receiving ART increased 
from 300 000 in 2002 to 9.7 million at the end of 2012 in LMIC (10). 
Despite the major developments in the response to the HIV/AIDS 
endemic, the same expansion in strategies to monitor and control the 
disease progression in patients before and during initiation of ART has not 
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equally advanced in these settings. In the World Health Organization´s 
(WHO) report on drug resistance from 2012, an increase of transmitted 
drug resistance mutations (TDR) were observed at the end of 2010 in 
LMIC. The increase of TDR was associated with greater availability of 
ART (11). As one of the targets in the 2011 United Nations Political 
Declaration on HIV and AIDS, 15 million people with HIV are planned to 
be on ART by 2015 (12). In settings with inadequate monitoring systems, 
the wider use of ART increases the risk of TDR (13-16), which may lead 
to treatment failure and imperil available therapy regimen options. 
In clinical settings and surveys, the methods utilized to analyze drug 
resistance mutations (DRM) are restricted and can only detect mutations 
present in more than 20% of the total viral population (17-19), which may 
underestimate the existing prevalence since drug-resistant strains may be 
present in viral quasispecies consisting of less than 20% of the population. 
In the beginning of this thesis, the role and the impact on treatment 
outcome of such undetectable drug-resistant viral populations was unclear. 
Therefore there was a need to explore more sensitive assays that could be 
used for this purpose. As ART is becoming more available globally, the 
demand on feasible and sensitive methods to detect drug-resistant viral 
strains is more urgent than ever. For this purpose we have used allele-
specific PCR (AS-PCR) assays, which have the capacity to detect viral 
populations that are present down to 0.1% of the total population (20-22) 
in Papers I-III, and a more recent approach, next generation sequencing 
(NGS) (23, 24) in Paper IV. Consequently, the overall aim of this thesis 
was to address these issues further and to investigate the potential 
usefulness of these sensitive assays in detecting drug resistance.    
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Figure1. Illustrating the progress in people receiving treatment in low- and middle-income countries 
and percent of eligible people receiving antiretroviral therapy at the end of 2012 (25).  
 
1.1 THE HEART OF THE HIV PANDEMIC: SUB-SAHARAN 
AFRICA 
Two-thirds of the world’s HIV infected population lives in sub-Saharan 
Africa, which makes it the hardest hit region of the pandemic. Women 
constitute more than half of the infected and more than 90% of the 
pregnant women with HIV reside in this region (26). sub-Saharan Africa 
has also the highest burden of HIV-infected children, accounting for at 
least 90% of the known 3.3 million children living with HIV today (27). 
The HIV treatment programs in Africa are mainly funded externally and 
the main focus is to provide affordable ART for both treatment and 
prevention (28, 29). Due to the wider access of ART, 7.5 million people 
received treatment at the end of 2012 compared to only 50 000 a decade 
earlier (29). This has resulted in a decline in both new HIV-infections and 
AIDS-related deaths by 40% and 22% respectively (5). However, the 
coverage between the countries varies markedly; in Botswana, Namibia, 
Rwanda, Swaziland and Zambia the ART coverage was more than 80% 
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while it was less than 20% in Madagascar, Somalia and South Sudan at the 
end of 2011 (26). 
Initiation of ART is a life-long commitment and needs to be monitored 
regularly. In high-income countries monitoring of patients was introduced 
early (30-33) and is frequently updated in the routine health care system 
(34, 35). Monitoring strategies include measurement of viral parameters 
that are essential to determine individually for each patient to obtain an 
optimal treatment outcome. Among these parameters, viral load 
assessment and drug resistance profiling of the patient´s virus is vital to 
avoid treatment failure and onward transmission of resistant viral strains. 
In LMIC, the management of ART is based on WHO´s guidelines and 
recommendations. Due to the absence of viral load and drug resistance 
testing in these settings, the guidelines comprise clinical manifestations 
and measurement of immunological markers as therapeutic monitoring 
strategy. Even though WHO´s guidelines from 2010 recommends viral 
load testing as the preferred mode for treatment monitoring (36) the 
implementation of it in the health-care system is challenging for many 
high-burden countries. In high-income countries, drug resistance testing is 
usually highly recommended and carried out for each patient as a guide to 
select the most appropriate therapy option. Because initiation of ART is 
life-long, drug resistance testing is also an important clinical tool to 
monitor the emergence of possible drug resistance mutations during 
treatment. In resource-limited countries, where drug resistance testing is 
either generally not available or too costly to be implemented in the routine 
monitoring, WHO recommends the testing to be applied for public health 
assessments. The rapid scale-up of ART poses a risk for the emergence of 
drug resistance. Through the Global HIV Drug Resistance Network 
(HIVResNet) (37), WHO has initiated a global surveillance of the 
emergence and transmission of drug resistance and several African 
countries have participated in the surveys since 2004 (11). As mentioned 
earlier the results of the surveys already indicate an increase of TDR which 
in the longer term may create severe effects on existing therapy options in 
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the continuation of sub-optimal monitoring systems as ART is becoming 
more available.   
 
1.1.1 Ethiopia 
To investigate whether TDR is present after the roll-out of ART and the 
relevance of sensitive assays, we have studied HIV-1 infected patients 
living in Ethiopia. Ethiopia is located in the horn of East-Africa and is 
among the countries heavily affected by the HIV epidemic today. The 
epidemic is believed to have begun in the late 1970s or early 1980s in the 
country. The first cases of AIDS was reported in 1986 and currently about 
800.000 people are estimated to be living with HIV (38). Even though the 
number of infected people is still high a significant drop in new HIV cases, 
from 130 000 in 2001 to 20 000 at the end of 2012, have been reported 
since the beginning of the ART scale-up (10). 
In order to respond to the accumulating HIV epidemic in the country, 
Ethiopia approved a National HIV/AIDS policy in 1998 (39). The policy 
was a statement over HIV/AIDS-crisis as both a health and development 
problem with severe effects on the society that needed urgent interventions 
on a national level with the objective to provide environment for the 
prevention and the control of the disease. Later in 2002, when AIDS was 
declared as a national public health emergency by the government, the 
Federal HIV/AIDS Prevention and Control Office (FHAPCO) was 
established to organize and facilitate the implementation of the HIV/AIDS 
policy. Today, FHAPCO is the main coordinator of the national response 
to HIV/AIDS. Since its establishment, FHAPCO has developed several 
strategies and guidelines to implement the policy and to maintain the 
commenced progress towards universal access of treatment and care for 
people living with HIV (38). An important step towards this goal was the 
initiation of the Antiretroviral Treatment program consisting of guidelines 
on the use of ART in 2003 (40). Shortly after in 2004, the Ethiopian 
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government launched a free ART program which has resulted in 743 
public and private health facilities providing HIV treatment and care 
services through the country today.  Currently, the ART coverage has 
reached 71% of eligible HIV-infected people. This rapid expansion of 
ART access, with 265 000 people on therapy at the end of 2011 compared 
to only 11 000 in 2004 (41), has mainly been accomplished through major 
donors as the Global Fund, PEPFAR, the World Bank and the UN system 
(38).       
1.2 HIV/AIDS IN INDIA 
India is currently the home of the third largest HIV population in the world 
and with its high-burden epidemic it is among the 22 top priority countries 
in the global response to the HIV/AIDS pandemic (28). The first 
HIV/AIDS case was reported in 1986 and presently about 2.4 million 
people are living with HIV. A national response to HIV/AIDS epidemic 
was initiated shortly after the reported first incidences by the establishment 
of the National AIDS Control Programme (NACP) under the Ministry of 
Health and Family Welfare. The major objectives of the programme 
included preventive interventions among high-risk groups, increase 
awareness of HIV/AIDS in the country as well as amend surveillance 
strategies. The national commitment, together with the contribution of 
non-governmental and community based organizations, has resulted in a 
decline of the HIV prevalence from 0.39% in 2004 to 0.31% in 2009 (42, 
43).   
The HIV/AIDS prevention and care is supported by major donors as the 
World Bank, PEPFAR, the UN system and private donors like the Clinton 
Foundation (42). In 2004, free ART services were introduced as a part of 
the ART programme under the initiation of National AIDS Control 
Organizations (NACOs), which has at the present resulted in 292 health 
care centers providing treatment for HIV infected individuals (43). At the 
end of 2012 the ART coverage had reached 51%, corresponding to 
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570 620 people. However, an estimated 1000 000 HIV infected people are 
still in need of therapy (10). 
1.3 THE STATUS OF THE EPIDEMIC IN SWEDEN 
Compared to other regions in the world, Sweden has a low prevalence of 
HIV-1, corresponding to about 60 individuals per 100 000 inhabitants (44). 
The first cases of AIDS in the country were reported contemporary with 
the first incidences observed globally in the beginning of the 1980s (45). 
Later in 1985, HIV/AIDS was declared as a notifiable disease and brought 
under the regulation of the Communicable Disease Act (46). The act 
applies to all diseases that can be transmitted among people and that 
constitute a threat to all individuals’ health. A total of 9 891 HIV positive 
cases have been reported so far (47) and today (8
th
 of May 2014) 6477 
people are known to live with HIV (Swedish InfCare HIV national quality 
assurance registry). The Swedish HIV/AIDS response is controlled 
through the National strategy against HIV/AIDS and Certain Other 
Communicable Diseases (Prop.2005/06:60) which was issued by the 
Swedish government in 2005 (48), as a result of the United Nations 
Millennium Declaration on HIV/AIDS(6, 7). The strategy formed a 
framework of measures and targets to prevent the spread of HIV-infection 
in the Swedish society. From an international perspective the domestic 
HIV prevalence has been low and stable in Sweden but because of the 
prevailing circumstances, the global HIV/AIDS-crisis poses a threat also in 
countries that have established a control of the epidemic at an early stage. 
In the beginning, the epidemic was driven by men who have sex with men 
(MSM) and intravenous drug users (IDUs) infected in Sweden. During the 
years, the reported new HIV cases among these two risk groups in the 
Swedish epidemic has decreased and since the 1990s the highest number 
of new cases is consisting of migrants infected heterosexually before 
arrival to Sweden. During 2010-2011, a total of 516 new heterosexually 
acquired HIV cases were reported and of these the most common country 
of birth was Thailand (60 cases), Eritrea (44 cases) and Ethiopia (42 cases) 
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(47). This indicates that the majority of new cases in Sweden are presently 
associated to high-endemic countries with insufficient monitoring systems 
and thereby at higher risk of acquiring drug resistance. 
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2 THE SUBTYPES OF HIV-1 AND 
DISTRIBUTION WORLDWIDE 
HIV is categorized into HIV-1 and HIV-2 and both types are proposed to 
have passed to humans from chimpanzee (49, 50) and Sooty Mangabey 
monkey (51), respectively. HIV-1 is further divided into three main 
groups; group M (main), group O (outlier) and group N (non-M/non-O) 
(52-56) . In addition, a new HIV-1 lineage, denoted as group P, has 
recently been discovered in two individuals originating from Cameroon 
(57, 58).  While the prevalence of HIV-2 is mainly restricted to West 
Africa at low levels, HIV-1 group M is the major causative virus type of 
the HIV-1 pandemic. HIV-1 group M is further classified into nine 
subtypes from A –D, F-H, J, and K. Recombination between the different 
subtypes within this group has resulted in additional subtypes known as 
circulating recombinant forms (CRFs) and unique recombinant forms 
(URFs). Among the HIV-1 group M, subtype C (HIV-1C) is the most 
prevalent worldwide and is responsible for half of the infections globally 
(59, 60) (Figure 2). HIV-1C was described for the first time in the end of 
the 1980-thies, isolated from Ethiopian patients, by our research group 
(61). 
HIV-1C is common in sub-Saharan Africa, India, and Brazil while HIV-
1B, which is the third dominating subtype globally (11%), is common in 
Europe and North America (60, 62). In Ethiopia HIV-1C is predominating  
(61). HIV-1B is the most common strain in Sweden, although due to 
migration of HIV-infected people from high-endemic sites non-B subtypes 
have begun to accumulate as well (44, 63, 64). Thus, research results from 
our group suggest that CRFs will become dominating in Sweden within a 
few years of time (Personal communication, Ujjwal Neogi and Amanda 
Häggblom). 
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Figure 2. Prevalence of HIV-1 subtypes and distribution worldwide. Adapted from (60). 
 
2.1 THE VIRAL STRUCTURE   
HIV-1 is a retrovirus which belongs to the Lentivirus genus of the 
Retroviridae family. The virus is 100 nm in diameter and has a spherical 
shape (Figure 3). It contains two single stranded RNA molecules which are 
together with other viral enzymes surrounded by a capsid (p24) and a 
matrix (p17). These enzymes comprise the reverse transcriptase (RT), 
integrase (IN) and protease (PR). All enzymes have three distinct functions 
in the replication process, which is detailed in the next paragraph. The 
envelope, which encloses the capsid and the matrix, consists of a lipid 
bilayer derived from the infected host cell. The envelope contains two 
glycoproteins, gp41 and gp120, which are used in the virus-cell attachment 
upon infection. The genetic material of HIV-1 comprises 9 genes (Figure 
3). Of these,  three major genes (gag, pol and env) encodes the structural 
proteins and the enzymes while the remaining six genes codes for 
 20 
regulatory proteins (tat and rev) and accessory proteins (vif, vpr, vpu and 
nef) all required for a successful replication (65).   
 
Figure 3. HIV-1 structure (66) and  genomic organization  (67). The virus is 9kb long and has three 
open reading frames; gag, pol and env. 
 
2.2 THE VIRAL LIFE-CYCLE  
The HIV life-cycle involves several steps and is dependent on both viral 
and host-cell factors (Figure 4). Upon infection, the viral life-cycle is 
initiated through the attachment of the gp41 and gp120 unit complex on 
the viral envelope to the CD4 receptor (68, 69) and the chemokine co-
receptors CXCR4 or CCR5 on the host cell (70, 71). This virus-cell 
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interaction induces a fusion between the viral envelope and the cell 
membrane which is followed by the subsequent release of the nucleocapsid 
into the target cell.  Through a disassembly mechanism of the 
nucleocapsid, the viral contents are released into the surrounding 
cytoplasm of the target cell (72, 73). The exposure of the viral genome and 
enzymes initiates the reverse transcription process. This event occurs 
through a cellular tRNA molecule, which base pair with the viral RNA and 
forms the starting site for the reverse transcription, and the RT enzyme 
which transcribes the viral RNA genome into a double stranded DNA (74, 
75). During this process two identical sequences of DNA called as long 
terminal repeats (LTRs) are added at the both end of the dsDNA. After the 
reverse transcription the dsDNA is transported into the nucleus and 
integrated into the host chromosome by the IN enzyme through the LTRs 
(76, 77). As integrated the LTR regions act as a promotor for host cellular 
transcription factors. Subsequently the provirus DNA is transcribed to 
mRNA which is followed by splicing and transportation out to the 
cytoplasm from the nucleus (78). In the cytoplasm the mRNA fragments 
are translated to precursor proteins. After the translation the full-length 
mRNA, viral enzymes and proteins assemble at the host cell surface 
through the env proteins, which are inserted into the plasma membrane of 
the host cell after the translation and used as an envelope (79). From here 
the viral particle-complex buds from the host cell and subsequently the PR 
enzyme cleaves the gag and gag-pol polyproteins which engage the 
production of new infectious viral particles. At some occasions the 
provirus can become inactivated and remain in a latent state in the host 
cell. This can either occur during pre-integration or post-integration of the 
dsDNA into the host cell genome (80). This feature of the HIV 
pathogenesis is an important obstacle for the complete eradication of the 
infection from the infected body.        
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Figure 4. The HIV life-cycle involves several steps and is dependent on both viral and host cell 
factors  (81). 
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3 ANTIRETROVIRAL THERAPY 
In the beginning of the HIV pandemic, only one drug (AZT) was available 
and used as monotherapy for the treatment. Subsequently additional drugs 
as didanosine (ddI) and zalcitabine (ddC) were approved and together with 
AZT they introduced the first HIV-1 drug class, nucleoside reverse 
transcriptase inhibitors (NRTIs) (82). Later the drug lamivudine (3TC) 
was approved and rapidly became one important component in 
combination antiretroviral therapy (ART). The drugs within this class 
compete with the host cellular deoxy-nucleotides to be incorporated into 
the growing viral DNA by the RT during synthesis. In contrast to the host 
cellular deoxynucleotides, the nucleoside analogues lack 3’-hydroxyl 
group which prevents the incorporation of other deoxynucleotides and 
thereby terminating the synthesis of the viral DNA (83).  
However, due to the rapid development of drug resistance with 
monotherapy (84, 85), a second class of antiretroviral regimens, protease 
inhibitors (PIs), were introduced for the treatment of HIV-1 infection in 
1995. Thus, the treatment of HIV-1 became combination therapy and the 
beginning of the Highly Active Antiretroviral Therapy era (HAART). 
Saquinavir, ritonavir and indinavir were the first drugs approved within 
this class (82) and their chemical structure resembles the structure of viral 
peptides which are recognized and cleaved by the protease. Through their 
binding to the active site of the enzyme the proteolytic cleavage of the gag 
and gag-pol remains inactivated which in turn prevent the maturation of 
viral particles to infectious viruses (83). Combination therapy proved to be 
beneficial in terms of suppressing the viral load, preventing the rapid 
emergence of drug resistance and reducing the incidence of AIDS-related 
deaths among HIV infected patients. Consequently, a third drug class, non-
nucleoside reverse transcriptase inhibitors (NNRTIs), were introduced in 
1996 with nevirapine (NVP) as the first approved drug. Shortly after, 
delavirdine (DLV), which is not approved in Europe due to severe side 
effects and efavirenz (EFV) were added to this new drug class (86). In 
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contrast to the nucleoside analogues described above, the non-nucleoside 
analogues are non-competitive compounds which bind to the hydrophobic 
domain near the active site of the RT. This event leads to a conformational 
change of the enzyme which becomes less flexible and unable to continue 
polymerization of the viral DNA (83).   
As a result of monotherapy in the early days of the HIV pandemic many 
patients could not benefit completely from the HAART because of drug 
resistance to the available regimens. Due to this dilemma there has been a 
constant need of improving the antiretroviral treatment strategies and the 
drugs. Recently, second generation drugs with high genetic barrier have 
become available within the existing drug classes to overcome this 
challenge. Additional drug classes have also been introduced for the 
treatment of HIV-1, such as entry inhibitors, fusion inhibitors (87) and 
integrase inhibitors (INIs) (88) all targeting distinct stages of the viral life-
cycle. The different ART drug classes and their inhibitory mechanisms are 
illustrated in figure 5.    
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Figure 5. Antiretroviral drug classes and their inhibitory mechanisms in an HIV-1 infected host cell 
(89).  
 
The NRTI drug class is the cornerstone in combination therapy and the 
current guidelines recommend the use of two NRTIs together with one 
NNRTI or together with one PI/r. These guidelines are well implemented 
in high-income countries and at the present, FDA approved 27 single anti-
HIV pharmaceuticals and seven fixed-dose drug combinations (FDCs) 
belonging to the existing six different antiretroviral drug classes are in the 
use for HIV therapy (88). Although, access to all drug classes and the 
drugs within each class, varies markedly worldwide with the lowest 
availability in low- and middle- income countries.  
 
 26 
3.1 TREATMENT OF HIV-1 INFECTION IN SWEDEN: 
INDIVIDUALIZED MANAGEMENT 
All drug classes are available in Sweden with 23 single drugs and six 
FDCs. Several laboratory parameters, such as CD4+ T cell counts, HIV 
RNA viral load and drug resistance profiling, are important to assess the 
clinical care in order to maintain good adherence and optimal outcome of 
the treatment. CD4+ T cell count is a clinical parameter which is used to 
determine the disease state of the infected individual and is also a predictor 
of when to start therapy. In Sweden, ART is recommended to be initiated 
in HIV-1 infected patients with CD4+ T cells counts < 500 cells/µL. 
During therapy, HIV RNA viral load is the most important marker to 
evaluate the outcome of the treatment. A suppressive and effective ART is 
achieved when the viral load level is < 50 copies/mL in the infected 
individual and is usually combined with measurement of the CD4+ T cell 
count. Genotypic resistance testing (GRT) is an essential tool used to select 
the most effective treatment option. Earlier, GRT was carried out at ART 
failure only, but since 2002 it is performed routinely in Sweden also before 
at diagnosis, or if this has not been done, before initiation of ART in 
infected patients in order to identify drug resistance and thereby avoid 
treatment failure. Monitoring of patients is advised to occur twice-three 
times a year, depending on the clinical situation, with measurement of the 
above described parameters and other necessary blood markers but can be 
maintained more frequently, depending on special circumstances such as 
drug adherence problems or emergence of drug resistance (90). 
 
3.2 TREATMENT STRATEGIES IN LOW- AND MIDDLE-
INCOME COUNTRIES: A PUBLIC HEALTH APPROACH 
In contrast to Sweden and other high-income countries with an 
individualized management of ART and monitoring interventions, the 
standard of care in LMICs is based on the WHO’s public health approach 
(91). In the beginning, ART was mainly available in high-income 
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countries due to their expensiveness as a result of patent rights of the drug 
companies. However, the manufacturing of generic ARVs has made it 
possible to produce affordable drugs in a larger scale in the reach of HIV-1 
infected people living in resource-limited settings (92, 93). Even though, 
ART scale up has increased significantly in LMICs mainly, not all drug 
classes are available in these settings. The most accessible drugs belong to 
the NRTI [tenofovir (TDF), 3TC, ZDV, and emtricitabine] and NNRTI 
(EFV and NVP). Current recommendation is the use of 2 NRTIs together 
with one NNRTI in first-line therapy, which is administered as a once-
daily FDC (29, 91). Second-line and third-line regimens are not widely 
accessible because of high-cost, however the PI/r lopinavir/r and 
atazanavir/r are becoming more available and are recommended to be used 
together with two NRTIs as second-line ART.  
Recently, the treatment recommendations by WHO were revised and at the 
present the initiating of therapy is advised to begin at CD4+ T cell counts ≤ 
500 cells/mm
3
 in adult and adolescents, and regardless of CD4+ T cell 
counts in pregnant women. In monitoring of ART, viral load is the 
recommended mode and in the absence of access, the approach is to assess 
CD4+ T cell counts and to use clinical criteria’s (91). GRT is only 
performed for surveillance purposes and is not recommended to be 
implemented routinely (37).             
3.3 ART-PROPHYLAXIS IN THE PREVENTION OF VERTICAL 
TRANSMISSION OF HIV-1 
A major event that has led to a decrease of new infections worldwide are 
attributed to preventive treatment (ART-prophylaxis) in HIV-1 infected 
mothers and their children during pregnancy, labour and after delivery. 
Before ART-prophylaxis was introduced, the transmission risk from 
infected mothers to babies was estimated to vary between 14% (in Europe) 
and up to 50% (in Africa) (94). With the introduction of HAART, more 
potent drugs with less toxic effects became available and were therefore 
evaluated to be used as ART-prophylaxis. The first study to show a 
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decrease in the risk was conducted 1994 (ACTG 076) (95). In the study, 
the vertical transmission risk was reduced from 25.5% to 8.3% by 
administering the ZDV to non-breast feeding mothers during the second 
and third trimester of pregnancy and their infants during the first six weeks 
of life. However, due to its complex administration and expensiveness it 
was not a feasible therapy option in resource-limited settings. A few years 
later, another study published an alternative strategy in which single-dose 
nevarpine (SD-NVP) was administered at the onset of labour to the 
mothers and to their infants within 72 hours of birth, resulting in a decrease 
of the transmission risk by 50% (96, 97). Because of its simple use and 
cost effectiveness this intervention was recommended to be used in 
resource-limited settings by WHO. As a monotherapy, this strategy also 
increased the risk of developing drug resistance and several studies have, 
since the implementation of it, reported the emergence of drug resistance 
mutations in these patient groups (98-102). In the studies, the NNRTI drug 
resistance mutations Y181C and K103N was shown to be quickly selected 
in a large proportion of the women after exposure to SD-NVP. Currently, 
the recommendation in the prevention of vertical transmission is the use of 
combination therapy consisting of two or three drugs depending on the 
accessibility of treatment regimens. In the revised treatment guidelines 
from WHO a once-daily FDC consisting of TDF, 3TC and EFV is 
recommended in pregnant and breastfeeding women (91). However in 
settings with limited access to ART, SD-NVP is still widely used (28). In 
Paper III and Paper IV in which the focus were on LMICs, women who 
had received ART-prophylaxis were excluded from the studies.        
  29 
4 DEVELOPMENT OF DRUG RESISTANCE 
The therapy failure that were observed in patients treated with AZT in the 
early days of the pandemic revealed that monotherapy was insufficient in 
preserving the viral load suppressed and as a consequence, viruses with 
decreased sensitivity to the AZT emerged quickly in these patients. Today, 
the development of drug resistance to HIV-1 is ascribed to the highly 
genetic variability of the virus.      
 
4.1 HIV-1: A HIGHLY DIVERSE VIRUS 
The expression “survival of the fittest” is very well applied to HIV-1. The 
features of the virus create an advantage for its rapid adaptation and 
survival even under the most unbeneficial environments. The viral 
population in an infected subject is consisting of a pool of variants, called 
quasispecies, which have been generated from one or a few virus upon 
infection. This variability of the virus is attributed to three important 
characteristics; error prone replication, high turnover, and large population 
size. It is estimated that in untreated patients, the number of infected cells 
is about 10
8 
(103) and due to the short half-life (~2 days) of these cells, 
HIV-1 is dependent on infecting new cells at a very high rate. Due to very 
high replicative capacity, 10
10
-10
11
 viral particles are generated on daily 
basis (104). However, amongst these characteristics the error prone 
replication is the most critical for the emergence of drug resistance. The 
RT, which replicates the viral RNA into dsDNA, lacks proof reading 
activity and is responsible for one misincorporation per 10
4
 nucleotide 
incorporations. On average, one error per genome per replication cycle is 
introduced (105) and with each viral strain  that replicates, the pool of 
viruses will expand further and result in a highly heterogeneous HIV-1 
population (106). Within this pool of viruses the wild type strain is the 
most adapted to the host environment and therefore predominates the HIV-
1 population. Quasispecies on the other hand, which are less adapted 
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because of mutations, will be inferior and not equally fit to replicate at the 
same rate as the wild type strain (107).  
When the host environment change, e.g. during drug pressure, the 
conditions for replication capacity and survival will also shift within the 
viral population. If the mutation made by the RT is introduced in important 
drug target sites, it will lead to a selective advantage for the quasispecies 
carrying the mutation compared to the wild type virus, which will be 
sensitive to the drug. In prolongation of the drug pressure, the mutant 
quasispecies will outgrow the wild type virus and dominate the viral 
population with time. The replicative capacity of the mutant quasispecies 
is not as effective compared to the wild type virus, since mutation impairs 
protein function but in the continuation of drug pressure this is 
compensated by the accumulation of additional mutations which will 
improve the fitness and replication ability of the virus. However, if the 
drug pressure is interrupted, the wild type virus will become the dominant 
virus (83, 108). 
 
4.2 ACQUIRED AND TRANSMITTED DRUG RESISTANCE 
The introduction of HAART made it possible to target the virus at 
different sites of the viral replication at the same time, thus preventing the 
emergence of drug resistance and subsequent treatment failure. However, 
DRM can still be acquired in some patients, due to several factors but 
incomplete therapy adherence and sub-optimal treatment are usually 
common factors that contribute. In both cases, the levels of drugs will be 
too low to prevent the viral replication completely but sufficient to 
promote the emergence of mutant strains.  The level of resistance that may 
arise is dependent on the genetic barrier, which is the number of mutations 
required to induce drug resistance. Some drugs have a high genetic barrier, 
requiring the accumulation of several mutations to induce high-level drug 
resistance like PIs/r, while other drugs have a low genetic barrier for which 
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only a single mutation is sufficient for the emergence of drug resistance as 
NRTIs and NNRTIs. In the context of treatment outcome, the appearance 
of secondary mutations which may emerge to increase viral fitness, do not 
affect the drug susceptibility. Cross-resistance can also occur within drug 
classes, which may compromise alternative regimens options for continued 
therapy. 
HIV strains carrying DRMs can be transmitted between individuals, so 
called primary drug resistance. Transmission of drug resistant-virus has 
been observed to be less efficient compared to wild type virus because of 
loss of fitness in the absence of ART (109). The stability and reversion of 
transmitted DRMs has been shown to vary in when ART is not present 
(110). Some mutations, that decrease viral fitness, seem to revert back to 
wild type quickly (111) while others with little impact on the fitness can 
sustain for longer time (112).    
 
4.3 HIV-1 MINOR POPULATIONS 
Within the pool of quasispecies in treatment experienced patients with 
drug resistant viral strains, the viral populations are divided into major and 
minor populations. Like in treatment-naïve patients, the pool of 
quasispecies presented in these subjects is heterogenous (113). The major 
population is the dominant quasispecies and co-exists with minor (non-
dominant) quasispecies consisting of different resistant genotypes (113, 
114). As the evolution of both populations occurs independently from each 
other, the minor quasispecies can become the dominant population under 
circumstances that are beneficial for its outgrowth. As such, minor 
quasispecies may constitute a reservoir consisting of a mixture of various 
viral populations which may enhance the development of drug resistance 
(115). The emergence of drug resistance in minor HIV-1 populations is 
clearly a field that has been under intense investigation lately. Earlier, the 
limitation of techniques used to detect these has made it difficult to 
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understand their implications in clinical context. However, with recent 
more sensitive methodological approaches that are becoming more 
available, it has become possible to investigate their clinical significance 
further. Although the availability of such assays are restricted to high-
income countries and as a result the implication of minority populations  in 
non-B subtype infections have been less investigated as in comparison to 
the HIV-1B. 
 
4.4 VIRAL RESERVOIRS 
One of the major obstacles to eradicate HIV-1 in infected individuals is the 
persistence of the virus as a latent form in viral reservoirs. A viral 
reservoir can be defined as a cell type in which a replication-competent 
virus can persist even under prolonged suppressive HAART (116). Resting 
memory CD4+ T cells were the first reservoirs that were isolated for HIV-
1 (117). Normally, activated CD4+ T cells have a short survival after 
infection and dies rapidly (118). However, resting memory CD4+ T cells 
seldom get infected by HIV and therefore it is proposed that latency of 
HIV-1 is established through the transition of activated CD4+ T cells into 
resting memory cells which can serve as a viral reservoir (119). Within 
these cells HIV-1 is integrated into the host genome and becomes 
transcriptionally silent. During this resting state there is no virus 
production from these cells but upon activation the production will be 
induced. A major consequence of such latency is that it constitutes a 
barrier for HAART to reach and affect these cells since the drugs are not 
able to eliminate integrated virus. Another consequence is the possibility 
of drug-resistant viruses becoming archived in the cells during ART and 
remain in a latent form until activated.  
HIV-1 can also reside in anatomical sites, which may act as viral reservoirs 
because of the limited penetration of antiretroviral drugs to these locations. 
As a result of sub-optimal drug concentration, drug-resistant strains can 
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emerge and evolve in these sites despite drug pressure (116).  If exchange 
of drug-resistant viruses occurs to other sites of the body it may lead to 
treatment failure. Since HIV-1 invades the central nervous system (CNS) 
and the access of some antiretrovirals may be restricted to this site it can 
act as a viral reservoir (120). We have therefore in this thesis investigated 
to which extent distinct drug resistance patterns in the cerebrospinal fluid 
(CSF) differ compared to blood, in both major and minor HIV-1 
populations.     
 
4.5 DRUG RESISTANCE MUTATIONS 
In this thesis, we have focused on the NRTI associated mutations M184I/V 
and the NNRTI associated K103N and Y181C mutations. These mutations 
are key mutations within their respective drug class and can confer high-
level resistance to regimens which are frequently used in first-line and 
second-line therapy. In the WHO drug resistance report from 2012 an 
increase of TDR was observed in LMICs over time and the most 
commonly observed TDRs were the K103N, M184V, and Y181C (11). In 
high-income countries, while NNRTI associated TDRs have increased, 
NRTI associated TDRs have declined over time (121). 
4.5.1 The NRTI drug resistance mutations M184I/V 
The M184I/V mutations occur in the catalytic site of the RT and involve a 
single base substitution at codon 184 (Figure 6). This substitution results in 
two alleles, M184I were the amino acid methionine is replaced by the 
isoleucine (ATG → ATA) and M184V were the methionine is replaced by 
the amino acid valine (ATG → GTA) (Figure 7). Because these amino 
acids have different side chains compared to the methionine they interfere 
with the incorporation of the nucleoside analogues within the catalytic site 
(122, 123). The M184I mutation is the first one to appear but is quickly 
replaced by the M184V since this mutation has greater ability to induce 
higher replicative capacity (124). Both mutations arise rapidly and confer 
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high-level resistance to 3TC, FTC and low-level resistance to abacavir 
(ABC) and ddI (125) (Figure 6). However, these mutations do not confer 
cross-resistance to other NRTIs and is replaced by the wild type virus 
when treatment is interrupted.   
   
 
 
Figure 6.  The gene map of HIV-1. Reverse transcriptase gene and associated mutations M184I/V. 
The emergence of these mutations confers high-level resistance to the nucleoside reverse 
transcriptase inhibitors lamivudine and emitricitabine, and low-level resistance to didanosine and 
abacavir.  
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4.5.2 The NNRTI drug resistance mutations K103N and 
Y181C 
The NNRTI drug resistance mutations occur in the hydrophobic binding 
pocket close to the active site of RT (Figure 7). The K103N and Y181C 
occur through a single base substitution. The K103N appears in codon 103 
in the RT gene as two alleles (AAA → AAC, AAA → AAT) were the 
amino acid lysine is replaced by the amino acid asparagine, while the 
Y181C occurs in codon 181 as one allele (TAT →TGT) were the amino 
acid tyrosine is replaced by the amino acid cysteine (Figure 8). The 
appearance of Y181C and K103N reduce the affinity of NNRTIs (126). 
Both mutations can emerge within a few weeks (127, 128) and have minor 
influence on the viral fitness (128, 129). In general, the NNRTI drug 
resistance mutations are highly cross-reactive to the first generation 
regimens within the drug class. The K103N can confer high-level 
resistance to EFV and NVP while Y181C confers intermediate to high-
level resistance to all regimens within the drug class (Figure 7). 
 
 36 
 
Figure 7. The gene map of HIV-1. Reverse transcriptase and associated mutations K103N and 
Y181C. The K103N mutation confers high-level resistance to the non-nucleoside reverse 
transcriptase inhibitors nevirapine and efavirenz. The Y181C mutation confers wide-class resistance. 
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5 METHODS TO DETECT DRUG RESISTANCE 
Both genotypic and phenotypic tests are available to study drug resistance. 
In this thesis we have used genotypic methods. There are different 
genotypic approaches available for detection of DRM. We have used direct 
population based sequencing, AS-PCR and NGS. GRT involves detection 
of known DRM in the genes of HIV-1, which confer reduced susceptibility 
to ART.  
 
5.1 POPULATION BASED SEQUENCING 
The most conventional GRT approach is based on direct polymerase chain 
reaction (PCR) dideoxynucleotide sequencing (Sanger) (17). This 
approach is the preferred method as part of standard-of-care to guide ART 
and monitor DRMs in HIV-1 infected patients. Direct sequencing can be 
carried out using either in house methods or commercially available assays 
such as TRUEGENE® HIV-1 Genotyping Assay (Siemens) (130) and 
Celera ViroSeq® HIV-1 Genotyping System (Abott) (131). These assays 
produce a nucleotide sequence of the pol gene, covering the protease and 
the RT coding regions in the clinical sample. In addition, the integrase and 
the part of the env gene coding for the glycoprotein (gp) 41 can also be 
sequenced. The obtained clinical sequence is a consensus sequence 
generated from a population of viral genomes, hence the name population 
sequencing. The consensus clinical sequence is then aligned and compared 
to a reference sequence of laboratory wild type strain to determine the 
presence of possible mutations. The identification of which mutations are 
clinically relevant is performed by interpretation systems that 
determine/predict the level of reduced susceptibility to ARV regimens 
(132, 133). Even though standard GRT is the recommended approach to 
monitor DRMs by international guidelines (34, 35), these assays have their 
disadvantages. First, they are complex in the context of interpreting the 
many distinct mutations identified within a clinical sequence, which can be 
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time consuming as well as difficult to apply into ART management. 
Second, they are not sensitive enough to detect viral populations below 
20% of the total viral population, which may allow clinically important 
minor variants to become undetected. Although these assays are relatively 
inexpensive assays to monitor DRMs in high-income countries, they are 
not cost-effective and easy to implement in resource-limited settings. 
Recently more sensitive GRT methods have been developed, such as 
point-mutation assays (AS-PCR) and deep sequencing (NGS), which could 
be an alternative to study drug resistance and as well as an option to use in 
resource-limited settings by targeting key DRMs.    
          
5.2 ALLELE-SPECIFIC REAL-TIME PCR 
AS-PCR is a point-mutation assay that allows the detection and 
amplification of different alleles of a gene simultaneously. Although a few 
mutations can be analyzed at a time, it is currently one of the most 
sensitive assays that can be used to study drug resistance. In comparison to 
standard sequencing, the sensitivity of point-mutation assays is quite high, 
enabling the detection of viral populations down to 0.01% (21, 22). In 
addition, AS-PCR is less expensive and time-consuming as compared to 
other sensitive assays like single-genome sequencing and clonal sequence 
analysis (134).  
Distinguishable for AS-PCR is the use of specific primers targeted for the 
allele of interest in DNAs of unknown genotype. These primers are 
modified intentionally and can specifically amplify the target allele within 
a sample by forming a 3´mismatch with the DNA template, which is 
described more in detail in chapter 7. In our AS-PCR methodology, we 
have used real-time PCR, which allows the detection and measurement of 
the amount of amplicon generated at each PCR cycle as it occurs in real 
time. The amount of target DNA is quantified using fluorescent probes or 
DNA-binding dyes which is incorporated to the amplicon during the PCR 
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cycles. The real-time PCR instrument measures this fluorescence signal as 
it increase during each cycle, which is proportional to the amount of 
amplicon generated in the exponential phase of the reaction. The real-time 
PCR reaction is displayed as an amplification plot in which the fluorescent 
signal is plotted against cycle number for each sample (Figure 8). For each 
sample a threshold cycle value (Ct) is obtained in the exponential phase 
where the florescent signal crosses threshold signal of the assay used to 
distinguish relevant amplification signal from the background. With each 
amplification a standard curve consisting of known concentrations of DNA 
is also amplified with the specific primers and run in parallel with the 
unknown samples. The obtained Ct values for the unknown samples are 
then compared with the Ct values of the standards to calculate the amount 
of the target allele. By comparing the amount of different alleles it is 
possible to calculate their relative proportion within a sample (135). 
 
Figure 8. Allele-specific real-time PCR amplification plot. The measurement of the curve occurs 
where the fluorescence signal crosses the threshold signal of the assay. 
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In this thesis different AS-PCR assays with distinct detection 
methodologies were utilized to study drug resistance in HIV-1 infected 
patients. In Paper I and II, we used an AS-PCR assay that was developed 
by us to detect the NRTI M184I/V mutations by using fluorescent probes. 
In Paper III we designed two AS-PCR assays for the detection of the 
NNRTI mutations K103N and Y181C using DNA-binding dyes.  
 
5.3 NEXT-GENERATION SEQUENCING 
The field of sequencing technologies has been revolutionized by the recent 
approach with NGS platforms. The high throughput ability of these 
platforms has made it possible to generate massive sequence data from 
different biological systems in a single run. There are currently several 
options of platforms accessible for deep sequencing, such as Illumina, 
Roche 454, Ion Torrent. However, due to their expensiveness they have 
not been available on a wider scale until recently. The introduction of 
bench-top sequencing platforms with high throughput have been shown to 
reduce the running cost and time and therefore in comparison to 
conventional methods (136) may be more suitable option to be used in the 
clinical diagnostics.  
In Paper IV, we used amplicon sequencing approach with Illumina MiSeq 
to develop a NGS protocol for the identification of the key DRMs, 
including K103N, Y181C and M184V, to be used in large scale 
sequencing and surveillance of DRMs. Compared to other NGS platforms, 
MiSeq has been shown to be more advantageous in terms of reducing 
hands-on-time, providing simpler laboratory workflows as well as deeper 
sequencing capacity to detect single nucleotide polymorphisms with the 
lowest error rate (24, 137).  
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The methodology in Illumina platform is characterized by the approach 
sequencing by synthesis technology (SBS) which enables tracking of 
fluorecently labeled nucleotides as they are being added to massively DNA 
strands in a parallel mode. In our protocol we used targeted sequencing 
through which only small selected or defined regions of genes are 
sequenced. The target amplicon was amplified using barcoded primers 
followed by multiplexing of 24 samples together that makes it possible to 
analyze and sequence a large number of samples simultaneously. The gene 
specific primers with platform-specific oligonucleotide adapters and 
individual index containing specific nucleotide stretch are used as the final 
primer for nested PCR amplification and thereby making each sample 
distinguishable during the process of sequencing. As such, this approach 
enables pooling of samples which drastically increases the number of 
samples that can be processed and analyzed in a single run. Following the 
sequencing, the raw reads are quality controlled and aligned to a reference 
sequence for variant calling (138). The downstream analysis used in our 
protocol is described in more detail in chapter 7.   
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6 AIMS OF THE STUDY 
The main aim of this thesis was to study drug resistance in minor HIV-1 
quasispecies and evaluate three assays based on allele-specific PCR (AS-
PCR) and next generation sequencing (NGS), respectively.  
This was done through the specific aims stated below:  
 To study by AS-PCR to which extent M184I/V mutations emerge 
during the first phase of viral decay in therapy-naïve patients 
initiated on lamivudine-containing antiretroviral therapy (ART) of 
various potency. 
 
 To investigate by AS-PCR to which extent distinct drug resistance 
patterns, including M184I/V, appear in major and minor viral 
populations in the cerebrospinal fluid and blood compartments in 
patients failing lamivudine-containing ART. 
 
 To assess by AS-PCR, the occurrence of the K103N and Y181C 
mutations in minor populations of treatment-naïve Ethiopian 
patients living Ethiopia, East African patients who have migrated 
to Sweden and Caucasian patients living in Sweden. 
 
 To develop and evaluate a feasible and easy-to-use high 
throughput NGS protocol for the detection of DRMs in the RT-
gene, including K103N, Y181C and M184V, that can be applied 
in large scale surveillance in low- and middle-income countries.  
 
 
 
  43 
7 MATERIAL AND METHODS 
7.1 PATIENTS 
The samples that have been used in the different sub-studies have been 
obtained from both treatment-naïve and treatment-experienced HIV-1 
infected patients. Ethical clearance was obtained for all studies. For more 
detailed information about patients, ethical permits and statistical analysis, 
see respective papers. Below follows a brief description of the patients.  
In Paper I, patients from three different cohorts were used. Cohort 1 
consisted of 315 samples which were obtained from 43 patients with 
primary HIV-1 infection (PHI) enrolled in the QUEST study (139). The 
patients were initiated on quadruple-regimen containing 3TC very early 
after diagnosis. Samples were collected at baseline, 1-6 weeks into therapy 
and after treatment cessation, which occurred after a median of 2.5 years of 
therapy. Cohort 2 consisted of 14 chronically HIV-1 infected patients from 
a Nordic randomized multicenter study (NORTHIV). The patients were 
randomized to a triple-regimen containing 3TC, one other NRTI, and a PI/r 
or efavirenz. A total of 26 samples were included from this study, of which 
12 samples were taken at baseline and 14 samples were taken 4-12 weeks 
into therapy. Cohort 3 consisted of 15 chronically HIV-1 infected patients 
followed during routine clinical care at the Department of Infectious 
Diseases at the Karolinska University Hospital, Sweden. The patients were 
initiated on dual-regimen containing ZDV and 3TC during 1995-1998. 
From these patients 36 samples were obtained, of which 15 were baseline 
samples and 21 samples were taken 2-28 weeks into therapy. All patients 
in the three cohorts had no previous treatment experience when ART was 
initiated. 
In Paper II, 13 multi-therapy experienced patients were included. A total 
of 44 plasma and CSF samples were obtained. These patients, who had 
developed virological failure during 3TC-containing therapy, were a part 
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of a prospective longitudinal study conducted at the Sahlgrenska 
University Hospital in Gothenburg, Sweden (140).  
In Paper III, plasma samples from 191 treatment-naïve patients belonging 
to three different HIV-1 infected cohorts were included. Cohort 1 consisted 
of  92 Ethiopian patients attending various clinics in Addis Ababa, 
Ethiopia, during 2008-2009 before initiation of ART as a part of a clinical 
research cohort  (141). Cohort 2 consisted of 55 treatment-naïve East 
African patients who had migrated to Sweden from following countries: 
Ethiopia (n=26), Eritrea (n= 23), Somalia (n= 2), Zimbabwe (n=2), 
Tanzania (n=1), and Kenya (n= 1). Cohort 3 consisted of 44 Caucasians 
living in Sweden. The patients residing in Sweden were followed at the 
Department of Infectious Diseases at the Karolinska University Hospital, 
Sweden during 2002-2013. Women who had received prophylaxis for the 
prevention of vertical transmission were excluded from the study.   
In Paper IV, single peripheral blood plasma samples obtained from 
treatment-naïve HIV-1 infected patients belonging to three different 
cohorts were used. A total of 96 patients were included, of which 49 were 
Indian patients that had been followed during 2010 to 2013 at St. John's 
Medical College and Hospital, Bangalore, India, 17 were East African 
migrants and 25 were Caucasians living in Sweden that had been followed 
during 2003-2013 at the Infectious Disease Clinic at Karolinska University 
Hospital. The selection of the samples was done retrospectively and 
randomly among those who had sufficient amounts of frozen plasma 
available. 
 
7.2   RNA EXTRACTION 
The RNA extraction was carried out by using the QIAmp Viral RNA Mini 
Kit (Qiagen) for all patients included with exception of the patients 
described in Cohort 1 in Paper I for which RNA was isolated by using the 
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Total Nucleic Acid Isolation Kit (TNAI) on a COBAS Ampliprep 
instrument (Roche). 
 
7.3 REVERSE TRANSCRIPTION AND NESTED PCR 
In Paper I and II, the Moloney Murine Leukemia Virus (M-Mulv) RT 
and the Expand High Fidelity PCR System (both Roche) was used to 
synthesize the cDNA from the extracted RNAs. The cDNA was 
subsequently amplifed and nested in several rounds by using the Expand 
High Fidelity PCR System (Roche) and the Applied Biosystem PCR 
reagents.   
In Paper III and IV, the extracted RNAs were converted to cDNA by 
using the Superscript III First Strand Synthesis Supermix (Invitrogen) and 
Random Primers (Promega) for the Indian samples. The cDNA was further 
amplified and nested by using the Expand High Fidelity Plus PCR System 
(Roche Diagnostics) and high fidelity Taq DNA polymerase with proof 
reading activity Platinum® Taq DNA Polymerase, High Fidelity 
(Invitrogen, US) for the Indian samples in Paper IV. 
 
7.4 SEQUENCING 
Sequencing was conducted to investigate the presence of other DRM in the 
pol gene. In Paper I and II, the 1315 bp long cDNA fragment was 
purified with PureLink™ PCR Purification Kit (Invitrogen) and sequenced 
using the BigDye Terminator v3.1 Cycle Sequencing Kits on the ABI 
PRISM 3100 Genetic Analyzer (both Applied Biosystems). The obtained 
nucleotide sequences were aligned by using SEQUENCHER software 
(Gene Codes Corporation, USA) and edited manually. 
In Paper III, nested PCR products, which corresponded to a 1203 bp 
fragment in the 5’ half of the Pol gene, were purified with QIAquick PCR 
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purification Kit (Qiagen) and sent for sequencing to MWG operon (MWG 
operon, Germany). Sequences were edited by using the BioEdit software 
v7.2.5 (http://www.mbio.ncsu.edu/bioedit/bioedit.html). The identification 
of TDR was assessed according to the WHO 2009 list of mutations for 
surveillance of TDR (142) as implemented in the Calibrated Population 
Resistance tool (v5.0 beta) (143) available at the Stanford HIV Drug 
Resistance Database (hivdb.stanford.edu). 
In Paper IV, sequencing was performed using an in house method 
described in (144) for the Indian samples. The obtained 680 bp long 
fragment after the first round PCR was sequenced and edited using an 
automated web based sequence editor, RECall (beta v2.9). For the Swedish 
samples sequencing and editing were carried out as described in Paper III. 
The interpretation of TDR was performed using the WHO 2009 list of 
mutations for surveillance of TDR, as described above.   
 
7.5 SUBTYPE CLASSIFICATION AND PHYLOGENETIC 
ANALYSIS 
In Paper IV, HIV-1 subtyping was performed using partial pol sequences. 
Phylogenetic analysis was conducted using the subtype reference 
downloaded from Los Alamos database and the PhyML version 3.0 with 
the best fitted model predicted in FindModel (www.hiv.lanl.gov). 
 
7.6 ALLELE-SPECIFIC REAL-TIME PCR (PAPERS I-III) 
Different detection methods can be used in AS-PCR. In this thesis both 
TaqMan® and SYBR® Green I dye chemistries have been utilized for the 
investigation of the M184I/V, K103N and Y181C DRM. The principle in 
TaqMan® chemistry is based on the application of a fluorogenic probe 
which is specifically designed to detect the accumulation of the sequence 
of interest while in the SYBR® Green I dye chemistry the use of a specific 
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dsDNA binding dye is applied. The major difference between the both 
detection assays is that the fluorophore dye in SYBR® Green I dye 
chemistry will detect all dsDNA that are present, including non-specific 
PCR products, compared to the fluorogenic probe in TaqMan® chemistry 
which only allows the detection of specific DNA targets.     
7.6.1 Detection and quantification of the M184I/V mutations 
The quantification and detection of the M184I/V mutations were 
performed as described earlier in (145) and was carried out using the 
TaqMan® chemistry. A typical reaction set-up includes forward and 
reverse primers, fluorogenic probe and a DNA polymerase with a 5’ exo-
nuclease activity. 
In the amplification one forward primer and three reverse primers were 
used (Figure 9). Among the reverse primers two were mutant specific and 
modified through the introduction of mismatches at the -1 and -3 
nucleotide positions from 3’ end of the primer. These mismatches enable 
the amplification of the corresponding mutant (M184I/V) and prevent the 
amplification of wild type as well as other mutant HIV-1 DNA. The 
forward primer and the third reverse primer, which are non-specific, 
amplify all HIV-1 DNA that are present.  
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Figure 9.  For the amplification of M184I/V one forward primer and two mutant specific primers 
were used. The mutant specific primers were modified by mismatches introduced at the -1 and -3 
nucleotide positions from the 3’ end of the primer. These mismatches enable the amplification of the 
corresponding mutant sequence (M184V: ATG →GTG; M184I: ATG →ATA) and prevent the 
amplification of the wild type sequence (M184: ATG). The mismatches are indicated in bold and 
underlined. The forward primer and the non-specific third reverse primer amplify all sequences that 
are present. R, reporter; Q, quencher.   
The fluorogenic probe used in the amplification reaction is a DNA 
oligonucleotide which has two distinct functions carried out through a 
fluorescent reporter dye in the 5’end, which fluorescence at a specific 
wavelength, and through a quencher molecule in the 3’end, which 
quenches the fluorescence emitted from the reporter dye. During the 
reaction the probe hybridize to the complementary target DNA 
downstream of the primer site. As the elongation of the new DNA strand 
continues the DNA polymerase will reach the probe and cleave it through 
the 5’ exo-nuclease activity. This results in the dissociation of the reporter 
dye from the quencher and increased fluorescence emission which is 
registered by the thermal cycler. With each cycle more reporter dyes will 
be dissociated, leading to an increase in fluorescence signal proportional to 
the amount of amplification products. If the target DNA is absent the probe 
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will remain intact and will not emit light due to the close proximity of the 
quencher which will absorb the light.  
All reactions, including patient sample and standard controls, were carried 
out in an ABI Prism 7700 Sequence Detection System (Applied 
Biosystems) which generated an amplification plot displaying the amount 
of fluorescence in each cycle for each sample and standards.  The amount 
of HIV total population and mutant of each patient sample was calculated 
through non-specific (total population) and specific (mutant population) 
standard curves, consisting of plasmid viral DNA subtype B HXB2 strain 
introduced with M184V GTG mutation or M184I ATA mutation, as 
described in (20). By comparing the cycle threshold (Ct) of the patient 
samples with the Ct values for the standards the proportion of mutated 
virus in correlation to the total viral population was determined. The cut-
off for the M184V mutation was set to 1.0% and 0.2% for the M184I 
mutation. 
 
 
7.6.2 The detection and quantification of the K103N and 
Y181C mutations   
For the quantification and detection of the K1013N and Y181C mutations 
the SYBR® Green I dye chemistry was used. A typical reaction set-up 
includes similar contents as described for the TaqMan® chemistry but 
instead of a probe a reporter dye is used instead. During the reaction, when 
the extension phase begins and the new DNA strand is synthesized, the 
SYBR® Green I dye will bind specifically to dsDNA by intercalating 
between the base pairs. As the extension phase will continue the more dyes 
will bind to the dsDNA and lead to an increased fluorescence signal. 
During the accumulation of the PCR products in each PCR cycle more 
fluorescence will be detected and this increased signal is proportional to 
the amount of amplification products.  
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Mutant specific and non-specific primers were designed for the 
amplification of the K103N (AAC and AAT) and Y181C (TGT) mutations 
and for the total viral population, respectively. The primers were designed 
by choosing the maximum consensus sequence from alignments of 598 
HIV-1 subtype B and C sequences available from the Los Alamos 
National Laboratories HIV sequence database (www.hiv.lanl.gov). For the 
amplification of the K103N mutants the same reverse primer was used for 
all reactions. The forward primers on the other hand contained a mutagenic 
sequence at the 3’ end which enabled specific amplification of respective 
mutant (Table 1). In contrast, for the amplification of the Y181C, the same 
forward primer was used for all reactions and the reverse primers 
contained the mutagenic sequence which amplified the respective mutant 
(Table 1). In addition, each mutant specific primer was anchored at 
position -1 of the 3’end, creating a mismatch which increased the 
selectivity of the primers (depicted as bold and italic “I” in Table I).   
 
Application Denomination Sequences (5´→3´) Nucleotides
*
 
Nested-PCR A1 GAAAGAYTGTACYGAGAGACAGGCTAAT 2058-2081 
 A2 TTAATCCCTGGGTAAATCTGACTTG 3350-3373 
 B1 AGCAGGAGCYGAARGACAGGG 2135-2158 
 B2 TYCCCACTAACTTYTGTATRTCATTG 3315-3338 
K103N-
ASPCR 
D1-AAC CMGCAGGGTTAAAAAAGAIC 2839-2858 
 D1-AAT CMGCAGGGTTAAAAAAGAIT 2839-2858 
 D1-ALL CAYCCMGCAGGGTTAAAAAAG 2835-2856 
 D2 CTGTGGRAGSACATTRTAYTG 2982-3002 
Y181C-ASPCR E1 TCARTAYAATGTSCTYCCACAGG 2981-3003 
 E2-TGT ATACAARTCATCCATRTATTGIC 3091-3113 
 E2-ALL CTACATACAARTCATCCATRTATT 
3094-3117 
Table I.  Primer sequences and their binding sites.* Sequence numbering is relative to the HXB2 
laboratory reference strain. The mutageneic nucleotide is shown in boldface and underlined in allele-
specific real-time PCR (AS-PCR) primers. The incorporated intentional mismatch (A→I in K103 
and T→I in Y181) at the -1 position of the 3’-end is shown in boldface and italic. This intentional 
mismatch was incorporated only in the mutant specific primer in order to increase primer specificity. 
  51 
 
Plasmid controls were constructed as described earlier (22) and run in 
parallel with clinical samples. By using the primer pairs B1 and B2 (Table 
1) a 1203 bp DNA fragment of the reverse transcriptase gene of HIV-
1NL4-3 strain was amplified and purified before cloned into pCR4-TOPO 
cloning vector (Invitrogen). The obtained HIV-1 RT clone, pCR4-RT, was 
used as a template for QuickChange II Site-directed PCR mutagenesis 
(Stratagene) to create the K103N (AAAAAC, AAAAAT) and 
Y181C (TATTGT) mutant plasmids used for generating standard 
curves. All AS-PCR reactions were carried out in an ABI sequence 
Detector System 7500 (Applied Biosystems). AS described under section 
7.5.2, the amount of total population and mutant of each clinical sample 
was determined by using specific and non-specific standard curves. The 
proportion of mutant in each sample was calculated by comparing the 
obtained Ct values with Ct values for standards. The cut-off for detecting 
K103N (AAC and AAT) was set to 0.1% and for Y181C (TGT) was set 
to 0.25%. An amplification with AS-PCR mutant specific and non-specific 
primers is illustrated in Figure 10. 
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Figure 10. Schematic overview of primers design used in the allele-specific PCR assays. For  
K103N analysis, each patients sample was analyzed with mutant specific AAC (A) and AAT (B) 
primers as well as non-specific primers that amplified the total populations (C). In presence of 
K103N-AAC (A) and K103N-AAT (B) mutants, only specific mutant amplicons will be amplified 
when using mutant specific forward (MSFP) and a common reverse primer (CRP), respectively. The 
total viral populations in each sample were amplified using non-specific forward primer (NSFP) and 
the CRP (C). MSFP, mutant specific forward primer; CRP, common reverse primer; NSFP, non-
specific forward primer. 
 
The selectivity and accuracy of the AS-PCR assay was evaluated by 
mixing various proportions of mutant and wild type DNAs. The mixtures, 
in which the proportion of mutant ranged from 0.01 to 100%, were 
analyzed with each mutant specific (AAC, AAT, or TGT) and non-specific 
primer pairs.   
The cut-off for the assay background was determined as a mean Ct value 
from eight independent runs of 100% wild type template with mutant 
specific primers plus three standard deviations. 
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7.7 TAGGED POOLED HIGH THROUGHPUT AMPLICON 
SEQUENCING (PAPER IV) 
7.7.1 Targeted amplicon sequencing 
NGS was performed using Illumina amplicon sequencing with MiSeq at 
SciGenom Lab Pvt. Ltd, Cochin, India. First round PCR products 
described in section 7.3 were amplified and ligated to barcoded primers 
and Illumina specific sequence adaptors with P7 and P5 (Figure 11) using 
Phusion High-Fidelity DNA Polymerase (New England Biolab, MA). 
After gel separation and elution, 24 consecutive samples were pooled in 
each run with 30% PhiX control and subjected to pair end 2x300 base-pair 
reads.   
  
 
 Figure 11. Schematic overview of the primers, Illumina specific adapters with P5 and P7 used in 
the next-generation sequencing analysis. Twenty-four index sequences were used in the pooling of 
24 samples and run in a single lane of MiSeq. 
 
7.7.2 Bioinformatics analysis 
The bioinformatics pipeline for NGS is illustrated in Figure 12. In order to 
assure the quality of the raw fastq files, the FastQC program 
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(http://www.bioinformatics.babraham.ac.uk/ projects/fastqc/) was used. 
Low quality bases from the end of the read were removed based on a cut-
off value of >Q30 of the Phred value score. The Cutadapt program (146), 
was used to remove any adapter sequences, if present, from the read 
sequence. Using the Bowtie2 version 2.0.5 program (147), the trimmed 
reads were thereafter aligned to the reference gene segment (HXB2 
position 2813 to 3246). Samtools was used to identify the properly-paired 
aligned reads, which were taken for further analysis (148). The 
UnifiedGenotype caller in GATK-Lite program 
(http://www.broadinstitute.org/gatk/) was used to perform variant calling. 
Variants with a quality score >50% and a read depth of at least 5000X 
were taken further for annotation. An in house Perl script was used to 
calculate amino acid frequencies. Mutations, which had a frequency of 
>1%, were considered for interpretation. 
 
 Figure 12. Illustrating the bioinformatics pipeline for next-generation sequencing using Illumina 
MiSeq platform. 
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8 RESULTS 
8.1 SELECTION OF DRUG-RESISTANT HIV-1 DURING THE 
EARLY PHASE OF VIRAL DECAY IS UNCOMMON IN 
TREATMENT-NAÏVE PATIENTS INITIATED ON A THREE- 
OR FOUR-DRUG ANTIRETROVIRAL REGIMEN 
INCLUDING LAMIVUDINE (PAPER I) 
Treatment of HIV-1 infection comprises the use of combination therapy 
consisting of three different antiretroviral regimens  (149). The use of more 
regimens (≥ 4) has been shown to be beneficial in terms of enhanced 
antiviral activity and increased viral decay after start of therapy (150, 151), 
but these advantages are nevertheless accompanied by additional side 
effects (152). Although, the clinical benefits with long-term four-drug 
ART has not been confirmed. Low-level ongoing viral replication has been 
described in patients with undetectable viremia (153, 154) and in patients 
treated with as many as four-drug ART (155). To which extent infection of 
new cells occurs during the first period of viral decay after start of 
suppressive therapy and if viral replication can result in the early selection 
of drug-resistant viral populations is not completely understood. To 
address these questions further, the main objective of this study was to 
explore to which extent the M184I/V mutations are selected during the 
first phase of initiation of ART in treatment-naïve HIV-1 infected patients.      
In this study, three different cohorts consisting of treatment-naïve patients 
initiated on quadruple (n=43), triple (n=14) or dual (n=15) 3TC-containing 
therapy was included. All patients in the first group with quadruple therapy 
were treated at PHI while the patients in the remaining two groups were 
chronically HIV-1 infected at start of therapy. By using AS-PCR and 
sequencing the patients were investigated for the M184I/V mutations up to 
six months after therapy initiation. Patients with quadruple therapy were 
also re-analyzed for the M184I/V mutations after ART cessation. 
One patient developed the M184V mutation during the first phase of viral 
decay among the patients in the quadruple and triple ART groups. The 
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mutant proportion, consisting of 2.5%, was not detected until 6 weeks after 
start of therapy and disappeared in subsequent samples taken up to 16 
weeks.  
In the group with dual therapy, a higher proportion of patients (8/15) were 
found to develop resistance early compared to the other two groups (Table 
II). Resistant strains were selected after about 5 weeks of ART and was 
completed after 20 weeks (Figure 13). 
The appearance of mutant populations was found not to be associated with 
a significant increase in plasma viral load. In two patients viremia levels 
was observed to decline even further despite a dominant mutant population 
present as >90%, however it did not prevent therapy failure in all patients 
at a later time point.  
 
Table II. Patients initiated on dual treatment containing zidovudine and lamivudine. 
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Figure 13. Proportion of M184Vmutants in samples from patients during the first 30 weeks of dual 
drug treatment. ART, antiretroviral therapy; RTG/GTG, bases on the M184 site as determined by 
sequencing. 
 
Two patients were found to harbor M184I as minor population at baseline. 
In the first patient belonging to the quadruple therapy group, the mutant 
population was estimated to 0.5% and was not selected during the first 6 
months of therapy. However, after cessation of therapy it re-appeared 
again at about 1% of the total population. In the other patient included in 
the dual therapy group, the mutation was selected in samples taken 5 and 
16 weeks after therapy start as 0.3 and 8.4% of the total population, 
respectively.    
Compared to previous findings of the early selection of resistance in minor 
populations in treatment-naïve patients initiated on triple ART, in whom 
minority viral variants were able to replicate within the first months of 
suppressive therapy despite viral decline  (156), none of the 57 patients on 
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triple or quadruple therapy in this study had detectable viremia after 16 
weeks of treatment and only one patient was found to have resistance in 
the minor population. 
M184I/V mutants were selected after cessation of therapy in two patients 
included in the quadruple therapy group. In one patient M184V was 
detected in the major population consisting of >90% only one week after 
therapy cessation and in the other patient M184I was detected as 1.0% 8 
weeks after therapy cessation. 
 
8.2 DIFFERENCE IN DRUG RESISTANCE PATTERNS 
BETWEEN MINOR HIV-1 POPULATIONS IN 
CEREBROSPINAL FLUID AND PLASMA (PAPER II) 
The CSF can constitute a viral reservoir for HIV-1, in which the virus can 
continue to replicate despite suppression of blood viremia (157). The 
passage of some antiretroviral drugs is restricted through the blood-brain 
barrier (158), which in turn could facilitate the evolution of drug resistance 
in the CSF compartment (158-160). Resistant viral strains can also be 
exchanged between the two compartments (161) and lead to treatment 
failure. Earlier studies have reported differences in the occurrence of M184 
mutations between the CSF and blood compartments (162-164), but only 
in the major populations. No study has investigated the pattern in minor 
populations below the detection limit of standard sequencing. Therefore, 
the aim of this study was to investigate to which extent unique resistance 
patterns appear in both minor and major populations in CSF and blood.    
Forty-four plasma and CSF samples were collected from 13 multi-therapy 
experienced patients. All patients had developed virological failure during 
ART containing 3TC. Of these, seven patients provided longitudinal 
samples. Both plasma and CSF samples were analyzed by AS-PCR 
specifically for the M184I/V mutations and direct sequencing for the 
  59 
presence of other drug resistance mutations in the RT-coding gene. All 
results are presented in Table III.  
In one patient (patient 2) the M184V mutant was detected in the major 
populations in both compartments but declined in subsequent samples and 
was only detected as a small population (5.6%) in the plasma compartment 
only. 
In seven patients (1.1, 2:1, 4:2, 6:1, 7:1, 8 and 13:1-4), differences in 
resistance at other RT positions between viruses from the two 
compartments were detected by direct sequencing. In four of these 
patients, a major drug resistance mutation was detected in the CSF but not 
in the plasma while in the remaining three patients it was detected in the 
plasma but not in the CSF. All mutations were however observed to appear 
or disappear from the compartments in all patients with longitudinal 
samples. 
Another patient (patient 4) was found to harbor several thymidine-
associated mutations (TAMs) and the L74V mutation in both 
compartments. Five months after therapy switch to a non-ddI containing 
regimen all TAMs persisted in both compartments while the L74V only 
persisted in the CSF compartment. In patient 8, the NNRTI mutation 
K70R was detected in the CSF only.  
For patient 13, the differences between the viruses in both compartments 
were found to be more diverse. The patient had been exposed to several 
treatment regimens over the years but with adherence problems, which 
contributed to high HIV RNA values and low CD4 T-cell counts. In 
addition, the patient also had treatment interruption between sample points 
2 and 3. The M184V mutation was not initially detected in the first paired 
sample for this patient by either AS-PCR or direct sequencing but was 
detected in the second sample as dominating population in the plasma and 
as a smaller population in the CSF. In subsequent samples M184V mutant 
persisted in the dominant population in the plasma compartment but 
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disappeared from the CSF. Direct sequencing showed also the presence of 
NRTI (T215S) and NNRTI (K103N) mutations in the first paired plasma 
sample but not in the CSF. In subsequent samples for the patient additional 
NRTI and NNRTI mutations were detected in plasma, of which most did 
not appear in the CSF compartment until the third sample in a combination 
with wild type amino acids. As a result of regimen change between the 
third and fourth samples all mutations, with the exception of K70E, 
reverted to wild type in the CSF but not in the plasma.  
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Table III AS-PCR and direct sequencing results for the blood and CSF compartments. Differences between paired samples are shown in bold. *Suspicion of low adherence. 
†Treatment included the investigational non-nucleoside reverse transcriptase inhibitor loviride. 
‡
3TC and loviride were introduced 5 weeks before the sample date. §Preceded by 4-
week treatment interruption. ABC, abacavir; CSF, cerebrospinal fluid; ddC, zalcitabine; ddI, didanosine; <dl, below detection limit of minor variants; d4T, stavudine; EFV, efavirenz; 
IDV, indinavir; LPV/r, lopinavir + ritonavir; NFV, nelfinavir; RT, reverse transcriptase; SD, standard deviation; SQV, saquinavir; 3TC, lamivudine; TDF, tenofovir; ZDV, 
zidovudine.  
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8.3 MINORITY DRUG RESISTANT HIV-1 VARIANTS IN 
TREATMENT NAÏVE ETHIOPIAN, EAST AFRICAN AND 
CAUCASIAN PATIENTS DETECTED BY ALLELE-SPECIFIC 
REAL-TIME PCR (PAPER III) 
Transmission of drug-resistant virus has begun to accumulate in resource-limited 
settings (11, 16, 165-168). In WHO’s report on drug resistance this increase was 
found to be associated with the wider availability of ART in these settings (11). 
According to the report the drug resistance mutations at the positions K103 and 
Y181 of the RT-genome were more commonly observed. In the absence of 
adequate monitoring interventions this prevailing outcome may compromise 
available treatment strategies in the future. Lately, a slowly increasing trend 
among reported new HIV infections has been observed in Sweden (47). The 
majority of the cases were related to immigrants infected prior arrival to Sweden 
from high-endemic countries as Eritrea and Ethiopia. The methods for detecting 
drug resistance mutations in surveys are based on standard genotypic testing, 
which is not able to detect drug-resistant viral populations in the minor 
population. For this purpose we aimed at studying the prevalence of the two 
NNRTI key mutations, K103N and Y181C, in the minor population by 
designing sensitive AS-PCR assays.  
Three different patient groups consisting of 92 treatment-naïve Ethiopian 
patients living in Ethiopia, 55 East African migrant patients and 44 Caucasian 
patients residing in Sweden were included in the study.  
Each mutant-specific primer was tested for specificity and cross-reactivity by 
using wild type plasmids as a template. No cross-reactivity was found as 
determined by differences in Ct values between the wild type and mutant 
plasmid DNAs. The amplification efficiency of mutant and wild type standard 
controls with their corresponding mutant and non-specific primers demonstrated 
a high correlation (r
2
 > 0.99) and were run in parallel with each sample (Figure 
14).  
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Figure 14. Allele-specific real-time PCR standard curves. Mutant specific (Sp) and non-specific (NSp) 
standard curves of K013N AAC allele, K103N AAT allele and Y181C TGT allele. These standard curves 
were run in duplicate, parallel with each sample and used to determine the copy number of each mutant 
specific and total population of sequence amplifications of clinical samples. By comparing the samples Ct 
values with those of the specific and non-specific standard curves derived from the standard plasmid controls 
using the corresponding primers, the quantity of the patients’ mutant specific and the total population of 
sequences (amplified with non-specific primer) was determined. By dividing the quantity of mutant specific 
sequence by the quantity of the total sequences and multiplying by 100 the percentage of mutant specific 
sequences was obtained for each sample. Positive samples were repeated at least twice. Correlation 
coefficients (r2 ) were higher than 0.99 for respective standard curve. Sp: mutant specific amplification. NSp: 
non-specific amplification (amplify the total population of sequences). 
 
The specificity and selectivity of the AS-PCR assays was determined by mixing 
mutant plasmid DNA controls ranging from, 0.01% to 100%, with wild type 
plasmid DNA control. Amplification of the mixtures with mutant specific 
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primers in the background of wild type sequence allowed the detection of 
mutants (AAC, AAT and TGT) down to 0.01%, which was also confirmed by 
melting curve analysis (Figure 15). The cut-off for K103N (AAC and AAT) was 
set to 0.1% and for Y181C (TGT) 0.25% from replicates of two independent 
experiments. 
 
 
Figure 15. (A) Example of allele-specific real-time PCR amplification curves of cloned wild type and 
mutant TGT plasmid DNAs at different frequencies (raw data). The specificity and accuracy of the AS-PCR 
assay was determined by analyzing mixtures of mutant and wild type DNA standards ranging from 0.01to 
100% amplified with mutant specific primers in the background of wild type sequence. Amplification of the 
total population results always in the same Ct values, regardless of the amount of mutant DNAs present in 
the reaction. (B) Melting curve analysis. WT, wild type. 
 
Of 92 treatment-naïve Ethiopian patients living in Ethiopia AS-PCR detected six 
individuals harboring the major NNRTI mutation Y181C (6.5%) (Table IV). The 
proportions of Y181C mutants that were detected ranged from 0.25-4.5%. None 
of the patients harbored the K103N mutation. Because of the low number of 
patients with DRM at baseline, it was not possible to study any impact on the 
outcome of ART in this patient group. However, two patients with the highest 
mutant proportions developed treatment failure and died within three months 
after initiation of therapy. Direct sequencing was performed to investigate the 
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presence of other mutations in the pol gene. Two patients were found to have 
additional DRM (NRTI: L100IL and PI: M46L) (Table IV). 
AS-PCR detected NNRTI mutations in 2 individuals (3.6%) among the East 
African patient group who had migrated to Sweden (Table IV). One was a 
female with the Y181C mutation in the proportion 0.8% and the other was a 
male with the K103N mutation corresponding to 17.5% which was also detected 
by direct sequencing. Using direct sequencing, additional drug resistance 
mutations were detected in four patients (Table IV). Among these two harbored 
the NRTI mutation M184V, two had NNRTI mutations (1 K101E, 1 Y188L) and 
one patient had the PI mutation N88S.  
In the Caucasian patient group living in Sweden AS-PCR detected the Y181C 
mutation in two male individuals (4.5%). The proportions of the Y181C mutants 
were 3% and 10.3%, respectively (Table IV). None of the patients in this group 
harbored the K103N mutation. Direct sequencing revealed the presence of 
additional DRM in two patients, one case with T215S and one case with L90M. 
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       AS-PCR Direct sequencing 
ID Gender Subtype Year Origin CD4 VL 
log 
Y181C 
(%) 
K103N 
(%) 
RT-region PI-region 
East Africans living in Sweden 
1 M C 2003 Ethiopia 190 4.02   M184V  
2 M C 2003 Eritrea 270 5.57   M184V N88S 
3 M C 2005 Eritrea 281 5.15   K101E, 
Y188L 
 
8 M C 2009 Eritrea 186 5.13  17.5 K103N  
10 F B 2006 Tanzania 189 5.03 0.8    
           
Caucasians living in Sweden 
12 M B 2011 Belarus 530 2.75 10.3  N.Da  
13 M B 2008 Russia 14 5.22   V106I  
19 M B 2009 Sweden 330 3.57 3.0    
20 M B 2011 Sweden 230 5.29   T215S  
21 M B 2011 Lebanon 960 3.87    L90M 
           
Ethiopians living in Ethiopia 
24 F C 2008-2009 Ethiopia 48 6 0.28  L100IL  
26 M C 2008-2009 Ethiopia 184 5.80 4.46  N.Da  
27 F C 2008-2009 Ethiopia 37 5.76 0.85    
29 F C 2008-2009 Ethiopia 115 6 0.53  N.Da  
43 M C 2008-2009 Ethiopia 77 5.50    M46L 
44 F C 2008-2009 Ethiopia 90 5.40 0.25    
aND,  not done 
Table IV. Characteristics of East African, Caucasian and Ethiopian patients with drug resistance mutations. 
 
8.4 COST-EFFICIENT HIV-1 DRUG RESISTANCE SURVEILLANCE 
USING TAGGED POOLED HIGH THROUGHPUT AMPLICON 
SEQUENCING: IMPLICATIONS FOR USE IN LOW- AND 
MIDDLE-INCOME COUNTRIES (PAPER IV) 
DRMs is presently increasing among therapy-naïve HIV-1 infected individuals 
in LMICs, where standard genotypic testing is not a part of standard healthcare 
system due to its high cost. In addition, these assays are not sensitive enough to 
detect DRMs in the minor populations. New approaches with high throughput, 
like NGS, have become available. These methods have been found to reduce 
both cost and time in comparison to conventional methods (136) .   
Therefore, the main objective of the study was to design a feasible and simple-
to-use high throughput drug resistance protocol for the use in large scale 
surveillance in LMICs by using the MiSeq (Illumina) platform. 
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Ninety-six ART-naïve patients with different ethnic origin were included in the 
study. Of these 49 were Indian patients residing in India, 17 were East African 
immigrants and 25 were Caucasians residing in Sweden.  
Subtype classification revealed 73% of the patients harboring HIV-1 C and the 
rest of the patients harboring HIV-1 B. Two separate clusters observed within 
the HIV-1 C cluster corresponded distinguishably to the East African and Indian 
patients (Figure 16).  
Both GRT-PS and GRT-NGS detected DRMs in 6% (6/96) of the subjects, of 
which two had NRTI (T215S) and four had NNRTI (K103KN, K101E, M230L 
and Y181C) mutations respectively (Table V). Hence, GRT-NGS detected all 
mutations detected by GRT-PS. GRT-NGS detected additional DRMs in 7% of 
the subjects (7/96) with a conclusive prevalence of 13% (13/96) (Table VI). The 
prevalence of low abundance mutations (< 20%) detected only by GRT-NGS 
were 19% (4/21) in East African individuals residing in Sweden, 6% (3/49) in 
Indian patients and 3.8% (1/26) in Caucasian patients residing in Sweden. 
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Figure 16 . Phylogenetic analysis. Two separate clusters were identified within the HIV-1 C cluster 
corresponding to the East African and Indian patients, respectively and one HIV-1 B cluster for the 
Caucasian group. 
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Subtype 
 
Year of 
sampling 
Average 
Depth 
GRT-NGS 
GRT-PS 
Ethnicity  DRM Frequency 
C East African 2008 56902X Y181C 
M184V 
28.6% 
28.5% 
No 
No 
C East African 2009 7472X K103N 
M184V 
14.2% 
14.1% 
No 
No 
C East African 2009 17374X K103N 6.2% No 
C East African 2012 23379X K103N 4.2% No 
B Caucasian 2009 12296X Y181C 
Y188C 
37.4% 
22.2% 
No 
No 
C Indian 2013 146186X K101E 17.1% No 
C Indian 2010 15595X K103N 
Y181C 
13.9% 
79.6% 
No 
Y181C 
C Indian 2011 18993X K219Q 22.6% No 
B Caucasian 2011 18941X T215S  99.7% T215S 
C East African 2013 22376X M230L 99.8% M230L 
B Caucasian 2006 359396X K101E 98.9% K101E 
C Indian 2011 184849X K103N 68.7% K103KN 
C Indian 2012 12846X K103N 28.4% K103KN 
Table V. Primary drug resistance mutations (DRMs) detected by genotypic resistance testing, by next 
generation sequencing (GRT-NGS) and by population sequencing (GRT-PS). 
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9 DISCUSSION 
I have studied drug resistance in minor HIV-1 populations in treatment-naïve 
and treatment-experienced patients in various clinical contexts. In the first part of 
this thesis, we investigated to which extent selection of the important M184I/V 
mutation occurred during the early phase of viral decay in ART-naïve patients 
initiated on lamivudine-containing combination therapy of various potency. The 
selection of the M184I/V mutations were frequently detected in patients 
receiving dual therapy but was a rare event in those treated with more than two 
drugs. This implicates that the use of a highly potent drug combination is 
sufficient to prevent the emergence of DRM in the first phase of viral decay in 
adherent patients. We also investigated to what extent specific resistance patterns 
emerge in the CSF compartment in comparison to blood in multi-therapy 
experienced patients with virological failure during lamivudine-containing 
treatment. The pattern of DRM suggested that drug resistance can develop 
differently in different compartments and that anatomic sites like CSF can 
constitute as a viral reservoir for resistant viral strains. Although I did not 
specifically analysed blood samples obtained from patients living in LMIC, the 
methodology is likely to be of clear relevance of such studies sine M184I/V is 
one of the most commonly occurring DRM in such settings.  
In the latter part of the thesis we instead focused on the emergence of DRM in 
treatment-naïve patients originating from LMIC, where ART has rapidly 
expanded in contrast to monitoring interventions. We developed sensitive AS-
PCR assays to study TDR in an African population and investigated the 
prevalence of K103N and Y181C in treatment-naïve Ethiopian patients living in 
Ethiopia and East African migrants in Sweden in comparison to Caucasians 
living in Sweden. We also developed a feasible high throughput NGS protocol 
that can be used for the detection of key mutations as K103N, Y181C and 
M184V as well as any other DRM in the pol gene, in the surveillance of drug 
resistance in LMIC. Using NGS, patients originating from East Africa and India 
were compared to Caucasian patients living in Sweden. Both AS-PCR and NGS 
detected clinically important DRMs in minor quasispecies in the patients 
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suggesting that conventional direct population sequencing assays can 
underestimate the prevalence of DRMs and thereby the extent of TDR in such 
settings. It shall also be noted that the included patients were infected by either 
HIV-1B or HIV-1C showing the feasibility to develop methods for different 
subtypes.  
In this thesis drug resistance to only two drug classes, NRTI and NNRTI, were 
investigated because dual NRTI backbone together with one NNRTI regimen is 
the most recommended first-line therapy worldwide. In addition, in LMICs ART 
is being scaled up and the treatment of HIV-1 infected patients is only restricted 
to a few regimens were 3TC, EFV and NVP are key components of first-line 
therapy and other options is currently not available on a wider scale. In our 
studies of patients from LMICs we have focused on treatment-naïve patients 
since global trends of TDR in this category of patients have increased over time 
(121). In particular an increase of NNRTI drug-resistance has been observed in 
both LMIC and in Europe. The prevalence of TDR in Africa has increased from 
2.8% (2001) to 4.7% and is mostly driven by NRTI and NNRTI drug resistance. 
In Europe, the prevalence of TDR has declined over time from 11.5% to 10.9%. 
This decrease was associated with a decline in NRTI drug resistance. In contrast, 
the prevalence of NNRTI resistance increased over time in Europe but a slight 
decline has been observed lately (121, 169). However, the methodologies in 
these reports comprise standard GRT which may underestimate the prevalence 
of TDR. Even though a slightly declining trend of TDR has been observed in 
Europe it can revert due to migration of people from high-endemic settings with 
increasing TDR.   
The AS-PCR assays used in this thesis were designed and developed for the 
detection of only three major mutations; M184I/V, K103N and Y181C. These 
mutations are clinically important to assess since they confer high-level 
resistance to the most commonly used anti-HIV drugs presently and are therefore 
key mutations that can compromise the treatment management of a large number 
of HIV-1 infected individuals. Initially we focused on the M184I/V mutation in 
the beginning of this thesis because this mutation confers high-level resistance to 
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3TC, which is a preferred regimen in HIV therapy. Monotherapy with 3TC 
results in the rapid selection of M184I/V (170). This was also observed in 8 of 
15 treatment-naïve patients initiated on dual therapy with 3TC in Paper I, in 
whom selection of drug-resistant strains carrying M184I/V occurred after 
approximately 5 weeks and completed after 20 weeks. In monotherapy with 
3TC, the selection of M184I/V is associated with viral rebound (171). In 
contrast, the emergence of minor mutant strains in the dual-regimen group in our 
study was not associated with a significant increase in viral load, despite an 
increase in the proportion of mutants in five patients with serial samples. 
Subsequently all patients experienced treatment failure at a later time point most 
likely due to insufficient ART. The selection of M184I/V was in contrast rare in 
patients initiated on three or four drugs with 3TC. Only one patient developed 
this mutation during the first phase of viral decay. This patient had a minor 
M184V mutant after 6 weeks of ART and wild type during the following 10 
weeks. This suggest that low-level viremia during the first phase of treatment 
initiation originates from proviral DNA in long lived infected cells or trapped 
virus in follicular dendritic cells (118). Our findings imply that ART consisting 
of three or four drugs is necessary to avoid the emergence of drug resistance in 
the early phase of viral decay after therapy initiation in adherent patients.  
In Paper II we investigated the M184I/V mutation further by studying to what 
extent distinct resistance patterns occur in CSF compared to blood in both major 
and minor quasispecies as earlier studies using conventional assays have shown 
differences in the occurrence of the M184I/V mutation in both compartments 
(162-164). In our study differences in the pattern of resistance were also 
observed frequently in CSF and blood in both minor and major populations. 
Using AS-PCR, differences were observed mainly in the proportion of mutated 
virus. Some samples though had low viral load, which may have contributed to a 
decrease in sensitivity of the AS-PCR assay, and could be an explanation for 
some of the differences in the proportion of the M184I/V mutations that were 
observed. In twelve paired samples from eight patients, differences were found 
in both major and minor populations between plasma and CSF. Of these, eleven 
samples showed a mixed population with semi-quantitative differences in M184 
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mutants and wild type virus. Only one patient harboured a minor resistant 
M184V population using AS-PCR and wild type using sequencing in the plasma. 
Although, this patient had this mutation as detected in the major population in 
the previous samples in both compartments but declined during following time 
points, likely as a result of low adherence. However, in overall there was a good 
correlation between the results obtained by AS-PCR and sequencing. 
Differences in resistance between viruses in the two compartments were also 
observed in other RT positions in seven patients using sequencing. In four of the 
patients a major mutation was detected in the CSF but not in the plasma, while in 
the remaining three patients a major mutation was found in plasma but not in the 
CSF. In serial samples belonging to six of these patients, all mutations were 
found to appear or disappear from the compartments, suggesting that the 
differences most likely were related to the selective drug pressure than distinct 
evolutionary pathways. The differences in viral resistance pattern were even 
more frequently observed in the patient who had been exposed to several 
treatment regimens as a result of adherence problems. This patient, who 
provided longitudinal samples, developed NRTI and NNRTI mutations initially 
in the plasma compartment, and in subsequent samples they also appeared in the 
CSF compartment in combination with wild type amino acids. However, when 
treatment was changed almost all mutations reverted to wild type in the CSF but 
not in the plasma. The M184V mutation followed a similar pattern, from being 
absent in the first paired samples it occurred as a dominant population in the 
plasma and as minor population in the CSF in the subsequent samples. As 
treatment switched, the mutant remained as dominant population in the plasma 
but disappeared from the CSF. This suggests that the differences in drug 
resistance development and exchange between the CSF and blood compartments 
can occur more frequently than anticipated.          
In addition to the M184I/V mutation we chosed to study the K103N and Y181C 
in the latter part of this thesis because there is strong evidence of their 
accumulation in resource-limited settings currently. In WHO’s drug resistance 
report these mutations were the most common mutations found in ART-naïve 
patients in LMICs (11). A global collaborative study to assess the prevalence of 
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HIV drug resistance in therapy-naïve patients in LMICs reported the K103N 
mutation in more than half of the HIV infected African patients with NNRTI 
resistance (168). In addition, the study also reported on the urgent need of 
feasible and sensitive assays for the detection of key mutations that could be 
implemented to monitor key DRMs at the population level in settings with 
inadequate resources. Standard GRT is not a feasible option in these settings, 
because it is complex due to extensive labor and as well as to costly to maintain 
regularly. We therefore designed a sensitive AS-PCR assay for the detection of 
K103N and Y181C in Paper III, and a cost-effective, easy-to-use high 
throughput NGS protocol for the detection of K103N, Y181C and M184V 
mutations that could be used to monitor key DRMs in Paper IV.   
Our AS-PCR assay in Paper III was found to be highly sensitive and selective 
with the capacity of detecting HIV-1 mutants down to 0.01%. A conservative 
accuracy of 0.1% for K103N and 0.25% for Y181C was obtained by mixing 
mutants in the background of wild type. The assay procedure is simple and easy 
to conduct but the design of mutant specific primers and standard curves needed 
careful handling to avoid underestimation because of polymorphisms at the 
primer binding sites in the target sequences. The primers were designed for 
amplification of only HIV-1C and HIV-1B, however these subtypes are the most 
dominant globally, and the primers were able to successfully amplify sequences 
of East African and Caucasian patients respectively. Using AS-PCR, we 
investigated the prevalence of TDR in Ethiopians infected with HIV-1C living in 
Sweden, East Africans with HIV-1C living in Sweden and compared the 
findings with the results of Caucasian patients with HIV-1 B living in Sweden. 
In the Ethiopian group, AS-PCR detected the Y181C mutation in 6.5% (6/92) of 
the patients with mutant frequencies ranging from 0.25% to 4.5%. All patients 
were newly diagnosed and confirmed no prior use of ART as well as prophylaxis 
for the prevention of vertical transmission. Additional DRMs were found by 
direct sequencing in the RT- and PR-coding region. The AS-PCR detected a 
higher prevalence of DRM compared to earlier studies in Ethiopia (172, 173), in 
which the prevalence ranged from 0% to 2.2% using conventional methods. In 
comparison, our result suggests that transmission of NNRTI-resistant virus 
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occurs in Ethiopia and standard GRT underestimates the prevalence of drug 
resistance. DRMs were also found in East African immigrants and Caucasian 
patients living in Sweden. In overall AS-PCR showed a good concordance with 
results obtained by direct sequencing in these two groups, however NNRTI 
mutations were detected in the minor quasispecies of both patient groups using 
AS-PCR. The prevalence of these minor mutants were found to be at the same 
level as the prevalence of resistance to NNRTIs (3.4%) across Europe obtained 
by conventional GRT (121).  
We developed a NGS protocol in Paper IV, which is an assay approach that has 
gained ground lately due to high throughput and time efficient properties. The 
implementation of routine GRT in the health-care system and surveillance of 
DRMs in high-endemic countries with poor recourses is still a challenge due to 
economical and infrastructure barriers. Conventional GRT assays are high-labor 
and less sensitive methods that further diminish the possibility to use them on a 
population level in LMICs. We therefore designed and evaluated a cost and labor 
efficient tagged-pooled NGS genotypic resistance testing approach for the 
detection of key DRMs. The NGS platform has mostly been available in high-
resource settings and has not been a feasible option for the use in LMICs due to 
its expensiveness. Our NGS protocol reduced the cost of running by 
multiplexing of samples. The cost of preparation of samples in NGS does not 
exceed the cost with conventional assays using in house techniques or 
commercial kits and is in addition further reduced in both cost and in labor per 
sample by pooling samples. In our protocol we used the MiSeq (Illumina) 
platform for which a run yielded around $750 to $1000 and pooling of samples 
yielded between $31 and $42 per sample. A significant additional reduction in 
cost can be obtained in large scale multiplexing, which makes this approach 
suitable for handling a large number of samples at the same time for a reasonable 
cost and without affecting the quality of the data (174). The preparation of the 
first round PCR for the Swedish and Indian samples were performed differently 
but the NGS analysis conditions with primers and amplification were the same 
for all of them which makes our protocol easy to adopt and applicable  in 
different protocol set-ups. 
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The method is very sensitive and therefore careful handling and precise 
preparation of samples is required to avoid highly variant read numbers as well 
as detection of very minute cross-contaminations, which are usually not detected 
by direct population sequencing. We were able to amplify and analyze three 
different patient populations with HIV-1 C and HIV-1 B which were confirmed 
by subtyping analysis showing distinct clusters of HIV-1 strains for respective 
patient group. Our assay was also found to be applicable to a broad range of HIV 
subtypes as the primers had > 97% sequence identity to all major pure and 
recombinant HIV-1 strains when aligned for nucleotide analysis in Los Alamos 
database. In comparison, the NGS assay was able to detect all DRMs detected by 
standard population sequencing. NGS identified also additional important low 
abundance DRMs (K101E, K103N, Y181C and M184V) that were undetected 
by standard sequencing. It is noteworthy that while DRMs, at frequencies >20%, 
in three out of four patients was detected by NGS they were undetected using 
standard population sequencing, which usually has a limit of detection >20%. 
However, an under-detection of DRMs using direct population sequencing has 
also been observed in comparison to deep sequencing in earlier studies (175, 
176). We detected the clinically important DRMs K103N and M184V as low 
abundance (<20% of the viral population) in five patients. The proportion of low 
frequency DRMs among the East African patients was found to be higher 
compared to Caucasian and Indian patients. Our results are in line with global 
trends of primary DRMs. While the prevalence of primary DRMs is low in 
Sweden (169), a significant increase has been observed in India (177) and in sub-
Saharan Africa, particular in East Africa (168).  With respect to drug classes, the 
increase of DRMs to the NNRTI class has been mostly observed, were K103N 
and Y181C were the most common mutations occurring in these settings over 
time since the roll-out of ART. 
We have detected DRMs in the minor quasipsecies of HIV-1 infected patients 
with different clinical backgrounds. We found that the emergence of drug-
resistant variant carrying the M184I/V mutations can be prevented in the early 
phase of viral decay when potent ART is used. Further, drug resistance can 
develop differently in the blood and CSF, in which we found the M1814I/V in 
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different proportions most likely as result of different kinetics of the mutations 
rather than distinct evolutionary pathways. We also designed a sensitive AS-
PCR assay specifically for the detection of two key NNRTI mutations K103N 
and Y181C to investigate the prevalence of TDR in Ethiopian patients living in 
Ethiopia and East African migrants residing in Sweden as compared to 
Caucasian patients living in Sweden. We found that the prevalence of TDR was 
higher in Ethiopian patients, suggesting that transmission of resistance strains 
occur in Ethiopia. In addition, we also developed a feasible easy-to-use high 
throughput NGS assay for detection of the key mutations K103N, Y181C and 
M1814V. Using NGS, East African migrants living in Sweden and Indian 
patients living in India was compared to Caucasian patients living in Sweden. 
The NGS detected a higher prevalence of low abundance NNRTI mutations in 
East African patients, which is in line with recent observations showing 
accumulating NNRTI resistance in these settings since the roll-out of ART.  
Although, the clinical cut-off and relevance of low abundance DRMs for 
treatment outcome is yet not defined there is studies which have shown that 
patients harboring drug-resistant viruses with a frequency ranging from as low as 
0.07% to 2.0% before therapy initiation has experienced treatment failure to 
first-line regimen containing 3TC and TFV in combination with EFV or NVP 
(178). In a systematic review and pooled analysis study, in which a strong 
association was observed between minority drug-resistant variants involving 
NNRTI resistance in particular and a dose-dependent increased risk of 
virological failure with first-line ART, found that this increased risk was also 
significant even at low minority frequencies presented as <0.5%  (179).   
The widespread use of ART globally is necessary and urgent, especially in low- 
and middle-income countries (LMIC) where the HIV pandemic has its epicenter. 
The recently observed gains in lives and the decrease in new infections is an 
important step towards the right direction in combating this devastating illness. 
Unfortunately, these breakthroughs can be challenged in the future due to 
unequally expanded monitoring strategies globally. We have in this thesis 
presented sensitive assays that can detect DRMs in the minor populations of 
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HIV-1 infected patients that are not identified with conventional GRT, which 
may compromise available regimens. Therefore, the question is not whether they 
exist or not and at what proportions, because as long as they emerge as a result of 
selective advantage under drug pressure they will most likely influence treatment 
outcome in HIV-1 infected patients independently if they pre-exist as de novo or 
due to transmission, the question is rather how we can optimize the management 
of ART globally. There is already evidence of virological failure within the first 
year in patients receiving first-line regimen in LMICs after the roll-out of ART 
(180) which are mostly driven by NNRTI and NRTI resistance (181, 182). As 
such, this poses a risk for the affected individual in settings with limited regimen 
alternatives as well as it is increasing the risk of transmission of clinically 
important DRMs in the absence of sufficient monitoring systems. In addition, 
infrequent monitoring of patients on ART has been associated with higher 
genotypic resistance to first-line regimens in these settings (181). The 
implementation of standard GRT is still a challenge for many high-burden 
countries, which influence the inadequate ART management. Therefore, the 
accesses of more feasible sensitive as well as easy to use techniques could 
simplify the monitoring DRMs and the guidance of treatment in HIV-1 infected 
patients in these settings.   
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10 CONCLUDING REMARKS  
The main findings of this thesis were: 
 Three sensitive AS-PCR assays were developed and found to detect 
point-mutations not identified by standard popoulation direct sequencing 
which is the present routine method in clinical care. 
 
 Using AS-PCR, selection of the important M184I/V mutations were 
found to be rare in the first phase of viral decay in patients with primary 
HIV infection or in patients with chronic infection initiated on potent 
three- or four-drug lamivudine-containing therapy.  
 
 In contrast, the M184I/V were selected in the decay phase in patients 
given less potent dual therapy, lamivudine and zidovudine, showing that 
highly potent therapy is necessary to avoid the emergence of drug 
resistance already during this early phase.  
 
 Distinct drug resistance patterns, in both minor and major HIV-1 
populations, can be found in the blood and CSF during therapy failure, 
showing that the CSF compartment can act as a reservoir for drug 
resistant strains, not found in blood. 
 
 Using AS-PCR, the clinically important K103N and Y181C mutations, 
can be found in minor viral populations of ART-naïve patients from low-
and middle-income countries and from  Sweden, not found by standard 
sequencing technique showing that transmission of drug-resistant strains 
occurs today. 
 
 A cost-efficient high-throughput NGS method using multiplexed 
amplicons can detect DRM in minor quasispecies and is a potential 
suitable approach for the surveillance of DRMs in LMICs. 
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11 FUTURE CONSIDERATIONS 
 
 The clinical significance and the clinical cut-off for minor DRMs are yet 
not defined and need to be established. 
 
 Using sensitive and cost efficient NGS assays with high throughput using 
multiplexed amplicons allows analysis of a larger number of samples and 
will thereby contribute significantly to the studies of the presence of drug 
resistance.  
 
 Implementation of such cost-effective and sensitive assays in the 
surveillance of DRMs should be considered in LMICs. 
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